Recently, much attention has been paid to PD-L1 expression in various solid tumors, due to the FDA's approval for anti-PD-1 antibodies in non-small cell lung cancer and melanoma with good efficacy and safety. This evidence concerns the gene CD274 and non-small cell lung carcinoma.